HCM

Chi-Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.52
-0.62
-1.93%
After Hours: 31.52 0 0.00% 16:45 08/07 EDT
OPEN
31.58
PREV CLOSE
32.14
HIGH
31.88
LOW
31.05
VOLUME
325.64K
TURNOVER
--
52 WEEK HIGH
32.50
52 WEEK LOW
14.74
MARKET CAP
4.48B
P/E (TTM)
-385.3301
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HCM stock price target is 35.28 with a high estimate of 45.00 and a low estimate of 29.91.

EPS

HCM News

More
Hutchison China MediTech Limited (HCM) CEO Christian Hogg on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 5d ago
Hutchison China MediTech Limited (HCM) Q2 2020 Earnings Call Transcript
Image source: The Motley Fool. Hutchison China MediTech Limited (NASDAQ: HCM)Q2 2020 Earnings CallJul 30, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Mr.
Motley Fool · 07/31 03:01
Hutchison China MediTech reports 1H results
Hutchison China MediTech (NASDAQ:HCM): 1H GAAP EPADS of -$0.36. Revenue of $106.77M (+4.5% Y/Y) Press Release
seekingalpha · 07/30 16:13
Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs
– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further NDAs submitted in China – savolitinib in MET3 Exon 14 skipping mutati
GlobeNewswire · 07/30 12:47
Chi-Med amends Elunate deal Lilly in China
Hutchison China MediTech (NASDAQ:HCM) and Eli Lilly (NYSE:LLY) amend their 2013 License and Collaboration Agreement for Fruquintinib. Under the terms of th
seekingalpha · 07/28 12:49
Chi-Med�s savolitinib nabs accelerated review status in China
Seeking Alpha · 07/28 09:58
Chi-Med teams up with Lilly to commercialize Elunate in�China
Seeking Alpha · 07/28 07:49
Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company (“Lilly”) today announce an amendment to the 2013 License and Collaboration Agreement on Fru
GlobeNewswire · 07/28 06:00

Industry

Pharmaceuticals
+0.19%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About HCM

Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.
More

Webull offers kinds of Hutchison China MediTech Limited stock information, including NASDAQ:HCM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HCM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HCM stock methods without spending real money on the virtual paper trading platform.